Cargando…

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists

Background: Good quality anticoagulation among patients with operated valvular heart disease is needed to reduce ischaemic and thromboembolic complications. There is limited evidence regarding factors that affect anticoagulation control in patients implanted with mechanical or tissue prosthetic valv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zulkifly, Hanis H., Pastori, Daniele, Lane, Deirdre A., Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917463/ https://www.ncbi.nlm.nih.gov/pubmed/36769789 http://dx.doi.org/10.3390/jcm12031141

Ejemplares similares

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials
por: Proietti, Marco, et al.
Publicado: (2016)

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
por: Pastori, Daniele, et al.
Publicado: (2018)

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2014)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation
por: Kim, Hyue Mee, et al.
Publicado: (2019)

Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores
por: Proietti, Marco, et al.
Publicado: (2016)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project
por: Xiong, Qinmei, et al.
Publicado: (2016)

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
por: Cases, Aleix, et al.
Publicado: (2021)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review
por: Violi, Francesco, et al.
Publicado: (2016)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
por: Oh, Seil, et al.
Publicado: (2018)

Correction: Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
Publicado: (2019)

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study
por: Lee, So-Ryoung, et al.
Publicado: (2017)

Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey
por: Lane, Deirdre A., et al.
Publicado: (2018)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
por: Wang, Kang-Ling, et al.
Publicado: (2015)

Non‐Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non‐Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis
por: Sitticharoenchai, Patita, et al.
Publicado: (2021)

Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis
por: Lane, Deirdre A., et al.
Publicado: (2018)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial
por: Clarkesmith, Danielle E., et al.
Publicado: (2013)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients
por: Mincu, Raluca Ileana, et al.
Publicado: (2019)

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
por: Zhao, Shujuan, et al.
Publicado: (2020)

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2019)

Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA‐AF Registry
por: Ding, Wern Yew, et al.
Publicado: (2022)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ufrci0cio8arasuig6p3ika7hu